Blooming Potential: BlossomHill Secures $100M Series B Funding for Small Molecule Cancer & Autoimmune Treatments

- BlossomHill Therapeutics, a biotech focusing on small-molecule drug design, has raised $100 million in a Series B financing round.
- Led by Colt Ventures, the funding includes investors such as OrbiMed, Cormorant Asset Management, Vivo Capital, Hercules BioVentures Partners, and others.
- Total capital raised by BlossomHill reaches $173 million after this round.
- The biotech, founded by J. Jean Cui (also a co-founder of Turning Point Therapeutics), aims to develop treatments for cancer and autoimmune diseases.
- Plans include moving their first two oncology programs into Phase 1 clinical trials and advancing others toward Investigational New Drug (IND) applications.
- Cui has designed three FDA-approved cancer drugs: Xalkori, Lobrena, and Repotrectinib.
- The company's drug design combines human intelligence, creative thinking, and proven drug design expertise to create small molecules with the potential to improve cancer and autoimmune therapy standards.